Tilray Brands (NASDAQ:TLRY) Trading 14.2% Higher – Should You Buy?

Tilray Brands, Inc. (NASDAQ:TLRY) shares traded up 14.2% during trading on Wednesday . The company traded as high as $8.16 and last traded at $7.87. 28,063,041 shares were traded during trading, an increase of 616% from the average session volume of 3,917,141 shares. The stock had previously closed at $6.89.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Analysts/technicals point to a recovery — Technical coverage says Tilray is showing an early reversal and breakout as U.S. cannabis rescheduling momentum builds, reinforcing a continuation of the rally. Tilray Brands (TLRY) Price Forecast: Cannabis Rescheduling Fuels Recovery
• Positive Sentiment: Political headlines fueling optimism — Coverage notes a renewed rally after President Trump urged the DOJ to quickly reclassify cannabis to Schedule III, boosting hopes for faster industry tailwinds and option-market bullish positioning. Tilray Stock Pops on New Trump-Driven Cannabis Hopes. Should You Chase the Rally?
• Positive Sentiment: Wall Street bullish note — Roth Capital’s Bill Kirk published a bullish outlook saying TLRY could rise >40% over 12 months based on three positive business developments, which can attract more buy-side interest. 1 Wall Street Analyst Says Tilray Stock Could Jump Over 40%. Should You Believe It?
• Positive Sentiment: Unusually heavy call buying — Traders bought ~45,077 call options today (about +89% vs normal daily call volume), signaling speculative bullish positioning that likely amplified the rally and implied volatility.
• Neutral Sentiment: Trading halt (LULD pause) — The stock experienced an exchange-imposed LULD pause around 11:49 AM due to rapid price movement; this is a volatility-control measure rather than a company-specific announcement.
• Negative Sentiment: Fundamental headwinds remain — Recent Q1 results showed an EPS miss and wide negative margins; analysts still model negative EPS for the year, so while headlines can drive short-term gains, underlying profitability issues could limit sustained upside.

Analyst Upgrades and Downgrades

TLRY has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, January 21st. Canaccord Genuity Group assumed coverage on Tilray Brands in a research report on Tuesday, January 27th. They issued a “hold” rating on the stock. TD Cowen reduced their target price on Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. ATB Cormark Capital Markets decreased their target price on Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating for the company in a research report on Thursday, April 2nd. Finally, Zacks Research raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 11th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $11.50.

Tilray Brands Stock Up 14.2%

The stock has a market cap of $917.25 million, a PE ratio of -0.58 and a beta of 2.00. The business has a fifty day moving average of $7.03 and a 200-day moving average of $9.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.79 and a quick ratio of 1.66.

Tilray Brands (NASDAQ:TLRY) last released its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.10). The firm had revenue of $206.73 million for the quarter, compared to analysts’ expectations of $201.35 million. Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.During the same quarter in the previous year, the business earned ($0.87) earnings per share. Equities research analysts anticipate that Tilray Brands, Inc. will post -0.55 earnings per share for the current year.

Hedge Funds Weigh In On Tilray Brands

Several institutional investors have recently made changes to their positions in TLRY. AQR Capital Management LLC lifted its stake in Tilray Brands by 1,839.7% in the first quarter. AQR Capital Management LLC now owns 607,054 shares of the company’s stock worth $399,000 after acquiring an additional 575,757 shares during the period. XTX Topco Ltd purchased a new position in Tilray Brands during the 2nd quarter valued at about $112,000. Cerity Partners LLC increased its position in Tilray Brands by 98.5% during the 2nd quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock valued at $38,000 after purchasing an additional 45,929 shares during the period. Ausdal Financial Partners Inc. bought a new stake in shares of Tilray Brands in the 2nd quarter valued at about $939,000. Finally, Bank of America Corp DE raised its holdings in shares of Tilray Brands by 26.5% in the 2nd quarter. Bank of America Corp DE now owns 311,810 shares of the company’s stock valued at $129,000 after purchasing an additional 65,379 shares in the last quarter. Hedge funds and other institutional investors own 9.35% of the company’s stock.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.